Results 251 to 260 of about 21,171,014 (388)

Laboratory testing for factor VIII and IX inhibitors in haemophilia: A review

Haemophilia, 2018
C. Miller
semanticscholar   +1 more source

New Technologies Empower Hemophilic Arthropathy Treatment: Focusing on Regenerative Medicine, Molecular Targeting, and Gene Therapy

Medicine Bulletin, Volume 2, Issue 1, Page 34-60, January 2026.
ABSTRACT Hemophilic arthropathy (HA), a major complication of hemophilia, is a chronic osteoarthropathy driven by repeated joint bleeding. Although traditional therapies such as coagulation factor replacement, physical rehabilitation, and surgery can manage symptoms, they cannot fundamentally repair established joint damage or break the pathological ...
Lin Sun, Yingnan Wang, Leyuan Zhao, Liqiang Lu, Fushan Hou, Chuan Yin, Kun Zhang, Yongqiang Hao, Jingke Fu   +8 more
wiley   +1 more source

Long-Term Experience with Acquired Haemophilia A: A 40-Year Single-Centre Study of Clinical Features and Outcome. [PDF]

J Clin Med
Roselli D, Malcangi G, Bonifacio MA, Ranieri P, Marino R, Mariggiò MA.   +5 more
europepmc   +1 more source

Measurement of plasma and platelet tissue factor pathway inhibitor, factor V and Protein S in people with haemophilia

, 2019
Paul E. R. Ellery, Ida Hilden, P. Thyregod, Nicholas D. Martinez, Susan A. Maroney, Joan Cox Gill, Alan E. Mast   +6 more
openalex   +2 more sources

Emicizumab in Previously Untreated Patients and Minimally Treated Patients With Hemophilia A: A Comparative Study Between Two International Cohorts

Pediatric Blood &Cancer, Volume 73, Issue 1, January 2026.
ABSTRACT Background Hemophilia A (HA) is a rare bleeding disorder caused by coagulation factor VIII (FVIII) deficiency. Prophylactic FVIII replacement therapy is essential for preventing bleeds, but it carries a risk of inhibitor development, especially in previously untreated and minimally treated patients (PUPs and MTPs, respectively).
Sarina Levy‐Mendelovich, Tlalit Barhod, Ivan Budnik, Jonathan Lancashire, Jesal Patel, Assaf Arie Barg, Einat Avishai, Rima Dardik, Tami Brutman Barazani, Tami Livnat, Jayashree Motwani, Gili Kenet   +11 more
wiley   +1 more source

Lipid Nanoparticles for Delivery of CRISPR Gene Editing Components

Small Methods, Volume 10, Issue 2, 22 January 2026.
The review presents a comprehensive overview of each component of lipid nanoparticles（LNPs）and their effects on editing efficiency. It specifically highlights strategies for achieving non‐liver delivery, aiming for broader applications in gene editing. Furthermore, this review summarizes the applications of LNPs in gene editing and offers insights for ...
Fan Wu, Nei Li, Yudian Xiao, Rohan Palanki, Hannah Yamagata, Michael J. Mitchell, Xuexiang Han   +6 more
wiley   +1 more source

Outcomes and Healthcare Resource Utilisation in Adults With von Willebrand Disease Receiving On‐Demand Recombinant von Willebrand Factor in the United Kingdom

European Journal of Haematology, Volume 116, Issue 1, Page 66-74, January 2026.
ABSTRACT Objectives We describe treatment outcomes and healthcare resource utilisation (HCRU) in adults with von Willebrand disease (VWD) treated on demand with recombinant von Willebrand factor (rVWF) in the United Kingdom. Methods Retrospective chart review of adults (≥ 18 years) with congenital VWD receiving first‐time rVWF for the on‐demand ...
Mike Laffan, Heena Howitt, Cheryl Jones, Sarah Brighton, Rosa Willock, Anna Sanigorska, Oliver Heard   +6 more
wiley   +1 more source

Comparing Real-World Outcomes of Prophylaxis with Extended Half-life Factor IX (rIX-FP vs. rFIXFc and N9-GP) for Haemophilia B: An Analysis of Medical Chart Data from Germany. [PDF]

Adv Ther
Olivieri M, Yan S, Yang Y, Tomic R, Linhoff T, Zhang X, Drelich D, Jakobs N, Miesbach W.   +8 more
europepmc   +1 more source

Outcomes and Healthcare Resource Utilisation in Adults With von Willebrand Disease Treated With Recombinant von Willebrand Factor in Surgical Settings in the United Kingdom

European Journal of Haematology, Volume 116, Issue 1, Page 75-84, January 2026.
ABSTRACT Objectives We describe treatment outcomes and healthcare resource utilisation (HCRU) in adults with von Willebrand disease (VWD) receiving recombinant von Willebrand factor (rVWF) in surgical settings in the United Kingdom. Methods Retrospective chart review of adults (≥ 18 years) with congenital VWD receiving first‐time rVWF for the ...
Mike Laffan, Heena Howitt, Cheryl Jones, Sarah Brighton, Rosa Willock, Anna Sanigorska, Oliver Heard   +6 more
wiley   +1 more source

Advancing care for women and girls with haemophilia: evidence from a comprehensive longitudinal analysis. [PDF]

Res Pract Thromb Haemost
Miesbach W.
europepmc   +1 more source